Cardiff: FDA Grants Fast Track Designation To Onvansertib

Cardiff Oncology (CRDF) announced the FDA granted Fast Track designation to onvansertib for treating KRAS- or NRAS-mutated metastatic colorectal cancer. The designation is based on Phase 2 trial data. Shares rose 12.82% in pre-market trading to $0.8192.

Original reporting
Published Nov 16, 2026, 12:16 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 16, 2026, 12:21 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefRegulation
Primary signal
$CRDF
Bullish
high confidence
Mentioned
$CRDF
Relevance
8/10
AlphAI data visualization · based on rttnews.com
Decision brief

The 30-second read

$CRDFBullishMed
01

Why it matters

Regulatory Fast Track designation can accelerate development timelines and increase valuation expectations.

02

Market read

First‑report FDA Fast Track news drives a 12.8% pre‑market rally, indicating high immediate relevance for traders.

03

What to watch

Potential competition from other KRAS/NRAS agents and the need for successful Phase 3 data.

Relevance 8/10Novelty 8/10Timing: pre‑market today

Background

Cardiff Oncology (CRDF) is a Nasdaq‑listed biotech developing onvansertib, a CDK9 inhibitor, for colorectal cancer.

Company-level read

Ticker impact

$CRDFBullishHigh confidence
Context

FDA granted Fast Track designation to onvansertib for KRAS/NRAS‑mutated metastatic colorectal cancer.

Expected impact

upward as the market prices in the potential approval pathway

Evidence & confidence

The designation is a material regulatory milestone for a biotech and the stock already jumped 12.8% pre‑market.

Market effects

May boost sentiment for other oncology biotech firms pursuing Fast Track or similar pathways.

Limited to US biotech sector; no broader regional effect.

Highlights FDA's willingness to expedite targeted cancer therapies, relevant to global biotech investors.

Counterpoint

Fast Track does not guarantee approval; clinical risk remains and the stock may be overbought after the jump.

Key entities

  • Mani Mohindru

    CEO of Cardiff Oncology, quoted on the Fast Track designation.

Related articles

$CRDFHighAI 9/10

Why is Cardiff Oncology stock surging today?

Cardiff Oncology (CRDF) stock rose 25% after FDA granted Fast Track designation to onvansertib for treating KRAS- or NRAS-mutated metastatic colorectal cancer. The designation is based on Phase 2 trial data showing a 72.2% response rate. CEO Mani Mohindru is presenting at the UBS Global Biopharma Conference. The stock's surge contrasts with a broader market decline.

$CRDFMed

Cardiff Oncology Reports Third Quarter 2026 Results and Provides Business Update

Cardiff Oncology, Inc. (CRDF) filed an SEC Form 8-K — Results of Operations and Financial Condition. Cardiff Oncology Reports Third Quarter 2026 Results and Provides Business Update Phase 2 trial remains ongoing, with median PFS not reached in the 30 mg onvansertib + FOLFIRI/bev arm versus median PFS of approximately 11 months in the combined SoC arms All patients remaining in t

$CRDFMedAI 8/10

FDA grants orphan drug status to Cardiff’s onvansertib for CMML

Cardiff Oncology (CRDF) received FDA Orphan Drug Designation for onvansertib to treat chronic myelomonocytic leukemia (CMML). The drug showed preliminary efficacy in a Phase 1 trial, with benefits including platelet response and stable disease. Orphan Drug Designation offers tax credits, fee exemptions, and market exclusivity. CRDF is developing onvansertib for other cancers as well.

$CRDFMed

Cardiff Oncology Reports Second Quarter 2026 Results and Provides Business Update

Cardiff Oncology, Inc. (CRDF) filed an SEC Form 8-K — Results of Operations and Financial Condition. Cardiff Oncology Reports Second Quarter 2026 Results and Provides Business Update Positive Phase 2 CRDF-004 data presented in an oral session at ASCO support advancement of 30 mg onvansertib plus FOLFIRI/bevacizumab into planned registrational program for first-line RAS-mutated m

$CRDFMedAI 8/10

Cardiff Oncology Announces $10 Million Registered Direct Offering

Cardiff Oncology (Nasdaq: CRDF) announced a $10 million registered direct offering. It will sell 8,571,429 common shares with warrants at $1.05 per share, plus insider participation of 731,707 shares at $1.435 per share. Warrants exercise at $1.31, exercisable after six months and stockholder-authorized share increase. Closing expected July 16, 2026.